Comparison of antisense oligonucleotide drug delivery systems

被引:45
|
作者
Weyermann, J
Lochmann, D
Zimmer, A
机构
[1] Karl Franzens Univ Graz, Dept Pharmaceut Technol, Inst Pharmaceut Sci, A-8010 Graz, Austria
[2] Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany
关键词
antisense oligonucleotide; nanoparticles; liposomes; protamine; proticles; polyoma; VPI; drug delivery systems; NMDA receptor;
D O I
10.1016/j.jconrel.2004.08.027
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Antisense oligonucleotides (AS-ONs) are specific drugs to inhibit gene expression at the transcriptional level. They possess a poor bioavailability and can be degraded by nucleases very rapidly. Therefore, a strong need for the development of oligonucleotide drug delivery systems exists. In the present study, two commercially available liposomes (DOTAP, lipofectin), one artificial virus capsoid (polyoma VP1), two cationic acrylate nanoparticles and two protamine-based nanoparticle preparations (proticles) were compared. Physical parameters of all carrier systems including z-average size, size distribution and surface charge regarding were determined. Cellular uptake was measured by a microplate fluorescence quantification method and, in addition, was visualized in mouse fibroblasts by confocal laser scan microscopy (CLSM). A comparison of cytotoxicity of the different drug delivery systems was performed in vitro using a MTT assay. Mouse fibroblasts which were stable transfected with the cDNA of a N-methyl-D-aspartate (NMDA) receptor also served as functional antisense oligonucleotide test system based on excitotoxicity (cell death). In addition, the efficiency of our oligonucleotide delivery systems was compared on the level of protein expression by Western blotting. Concluding the results, an increased uptake of the ON was found (2-18-fold) for all delivery systems compared to the free ON. Protamine-based nanoparticles showed a very low cytotoxicity in contradiction to all other carrier systems. Lipofectin could be identified as the most potent delivery system in terms of antisense effect, followed by protamine nanoparticles and DOTAP. Sequence-specific antisense effects up to 80% were observed in the functional cell death assay. The highest reduction of NMDA expression was obtained from liposomal preparations with approximately 60% analyzed by Western blot. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:411 / 423
页数:13
相关论文
共 50 条
  • [21] Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA
    Juliano, RL
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (02) : 132 - 136
  • [22] Comparison of novel delivery systems for antisense peptide nucleic acids
    Chiarantini, L
    Cerasi, A
    Fraternale, A
    Millo, E
    Benatti, U
    Sparnacci, K
    Laus, M
    Ballestri, M
    Tondelli, L
    JOURNAL OF CONTROLLED RELEASE, 2005, 109 (1-3) : 24 - 36
  • [23] Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
    David R Corey
    Nature Neuroscience, 2017, 20 : 497 - 499
  • [24] Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
    Corey, David R.
    NATURE NEUROSCIENCE, 2017, 20 (04) : 497 - 499
  • [25] Anti-Drug Antibody Assay for an Antisense Oligonucleotide
    Wojcinski, Mary
    Kuiper, Leslie
    St Charles, Jessica
    MOLECULAR THERAPY, 2024, 32 (04) : 437 - 437
  • [26] RGD Conjugated Dendritic Polylysine for Cellular Delivery of Antisense Oligonucleotide
    Le, T. D.
    Nakagawa, O.
    Fisher, M.
    Juliano, R. L.
    Yoo, H.
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2017, 17 (04) : 2353 - 2357
  • [27] Blended Block Polycation Micelles Enhance Antisense Oligonucleotide Delivery
    Hanson, Mckenna G. G.
    Grimme, Christian J. J.
    Kreofsky, Nicholas W. W.
    Panda, Sidharth
    Reineke, Theresa M. M.
    BIOCONJUGATE CHEMISTRY, 2023, 34 (08) : 1418 - 1428
  • [28] A Polyethylenimine-Linoleic Acid Conjugate for Antisense Oligonucleotide Delivery
    Xie, Jing
    Teng, Lesheng
    Yang, Zhaogang
    Zhou, Chenguang
    Liu, Yang
    Yung, Bryant C.
    Lee, Robert J.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [29] Reviewing antisense oligonucleotide therapy: part 2, delivery issues
    Das, SK
    Miller, KJ
    BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 1999, 12 (11): : 44 - +
  • [30] Local delivery of an antisense oligonucleotide for recessive dystrophic epidermolysis bullosa
    Mendes, R.
    van Wissen, L.
    de Jager, M. W.
    van der Ham, F.
    Brinks, V.
    Ritsema, T.
    Haisma, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S223 - S223